2022: The End Of The US Price Negotiation Debate?

 
• By Michael McCaughan

The Democratic party has been advocating for Medicare drug price negotiation authority in the US for almost two decades. The coming year may see it finally happen – or it might mean the issue is gone for good.

Drug questions on the Hill
• Source: Nielsen Hobbs; the Pink Sheet | Alamy images

More from Pricing Debate

More from Market Access